Skip to content

A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150

Pharmacokinetic Study of YM150 - A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01118559
Enrollment
24
Registered
2010-05-06
Start date
2009-11-30
Completion date
2010-01-31
Last updated
2010-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Pharmacokinetics of YM150

Keywords

YM150, Food effect, Healthy volunteer

Brief summary

This study is to evaluate the effect of food on the pharmacokinetics of YM150 in healthy male adult subjects.

Detailed description

To evaluate the effect of food on the pharmacokinetics of YM150 in healthy non-elderly adult male subjects using a 2×2 crossover design. Also, to evaluate the safety of YM150.

Interventions

DRUGYM150

oral

Sponsors

Astellas Pharma Inc
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
20 Years to 44 Years
Healthy volunteers
Yes

Inclusion criteria

* Body weight: ≥50.0 kg, \<80.0 kg * BMI: ≥17.6, \<26.4 * Healthy, as judged by the investigator or sub-investigator based on the results of physical examinations and lab tests

Exclusion criteria

* Received any investigational drugs within 120 days before the study * Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before the study * Received medication within 7 days before the study * A deviation from the assessment criteria of physical examinations or laboratory tests * A deviation from the normal reference range of coagulation test \[PT or aPTT\] * History of drug allergies * Upper gastrointestinal disease within 7 days before the study * Concurrent or previous hepatic, gastrointestinal, heart, cerebrovascular or respiratory diseases * Concurrent or previous malignant tumor * Previous treatment with YM150

Design outcomes

Primary

MeasureTime frame
Plasma concentration of YM150 and its metabolitesfor 3 days after drug administration

Secondary

MeasureTime frame
Safety assessed by AEs, vital signs, 12-lead ECG and lab testsfor 3 days after drug administration
PT (prothrombin time)for 3 days after drug administration
aPTT (activated partial thromboplastin time)for 2 days after drug administration
FXa (factor Xa) activityfor 1 days after drug administration

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026